Clinical Trial Update: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome [EARLY_Phase 1]

View source ↗

Summary

Early-phase Phase 1 trial evaluating tadekinig alfa, an interleukin-18 binding protein, as rescue therapy for CAR T cell–related cytokine release syndrome and H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Tadekinig Alfa (tadekinig alfa)

Snippet

Sponsor: University of Pennsylvania | Conditions: CRS - Cytokine Release Syndrome, HLH | EARLY_Phase 1 | Status: RECRUITING